Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_4
1
25%
Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (25.0%)
N/A3 (75.0%)

Trials by Status

recruiting125%
completed250%
active_not_recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingnot_applicable

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

NCT06620185
active_not_recruitingnot_applicable

Immune Response To Intranasal Influenza Vaccination

NCT01866540
completednot_applicable

The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response

NCT02642237
completedphase_4

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).

NCT02143882

Clinical Trials (4)

Showing 4 of 4 trials
NCT06620185Not Applicable

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

Recruiting
NCT01866540Not Applicable

Immune Response To Intranasal Influenza Vaccination

Active Not Recruiting
NCT02642237Not Applicable

The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response

Completed
NCT02143882Phase 4

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4